Marcus & Millichap (MMI) Q2 Earnings Report Preview: What To Look For

Marcus & Millichap (NYSE: MMI) is set to report Q2 results Thursday before the bell. The firm previously beat revenue expectations with $171.5M revenue, up 18.2% year on year. For the upcoming quarter, analysts expect revenue growth of 12.8% y/y. The article cites an average analyst price target of $28 versus a $30.88 share price.

Original reporting
Published Aug 5, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Marcus & Millichap (MMI) Q2 Earnings Report Preview: What To Look For — source image
Decision brief

The 30-second read

$MMINeutralMed
01

Why it matters

Traders can use the stated consensus revenue growth (12.8% YoY) and the prior-quarter beat context to gauge upside/downside risk versus expectations, but there is no new fundamental disclosure in the text.

02

Market read

Earnings preview for MMI with consensus revenue growth and peer read-through, useful for positioning into the print but not a new catalyst.

03

What to watch

The preview emphasizes revenue growth and EBITDA beats but does not detail margin, guidance, or balance-sheet items that often drive earnings-day repricing.

Relevance 4/10Novelty 3/10Timing: ahead of Thursday pre-bell Q2 earnings

Background

Marcus & Millichap will report Q2 results this Thursday before the bell; the article frames expectations using last quarter’s beat and current consensus.

Company-level read

Ticker impact

$MMINeutralMedium confidence
Context

Marcus & Millichap is set to report Q2 results this Thursday before the bell, with revenue growth and consensus expectations outlined.

Expected impact

Likely modest volatility around the release, driven by whether reported revenue and EBITDA beat or guidance deviates from the 12.8% YoY revenue expectation.

Evidence & confidence

The article provides expectations (12.8% YoY revenue growth) and notes a prior beat, but it does not disclose any new company-specific development beyond the upcoming earnings timing.

Market effects

Real estate services peers (Compass, JLL) already reported, offering read-through for brokerage demand and transaction activity expectations.

No specific regional demand signals are provided beyond the segment-level peer read-through.

Limited, as the article is focused on a US-listed brokerage earnings preview.

Counterpoint

A prior revenue beat does not guarantee another beat; if transaction volumes or margins soften, the stock could re-rate lower despite consensus reconfirmations.

Key entities

  • Marcus & Millichap

    US real estate brokerage and services firm scheduled to report Q2 results this Thursday before the bell.

  • Compass

    Peer that already reported Q2, cited for year-on-year revenue growth and beat magnitude.

  • JLL

    Peer that already reported Q2, cited for revenue growth and beat magnitude and subsequent stock move.

Related articles

$MMIMed

Marcus & Millichap, Inc. (MMI): Results of Operations and Financial Condition

Marcus & Millichap, Inc. (MMI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 er-q226earningsrelease.htm EX-99.1 Document MARCUS & MILLICHAP, INC. REPORTS PRELIMINARY RESULTS FOR SECOND QUARTER 2026 Revenue Grew 17.8% Compared to Second Quarter 2025 Net Income of $0.10 Per Diluted Share for Second Quarter 2026 CALABASAS, Calif., August 6, 2026 --

$MMIMed

Update on MMI and Further Investment

Crystal Amber Fund Limited said it invested a further $8.2 million in Morphic Medical Inc (MMI) since Feb 16, 2026, in three tranches at $0.48 per share, with the latest on July 31, 2026. The fund now holds 435,992,719 MMI shares (~97.9%). MMI reported FDA study pause removed, sites up to 40, US enrolment by early 2028, and Germany NUB status.

$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.